AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20456105 — intervention group
Group type: COMPARATOR
Intervention: Pads with cellulose core; evaluated for lotion transfer.
Number of subjects: 0
Study 20456105 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical in-use study on second series of test products; evaluated for lotion transfer.
Number of subjects: 0
Study 18513551 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy after an 8-hour fasting period (Group A)
Number of subjects: 129
Study 18513551 — intervention group
Group type: COMPARATOR
Intervention: Capsule endoscopy after drinking 2 doses of 45 mL oral sodium phosphate (NaP) (Group B)
Number of subjects: 129
Study 18513551 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy (both groups)
Number of subjects: 129
Study 16129742 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate degradable cement (Norian SRS) augmentation
Number of subjects: 112
Study 16129742 — intervention group
Group type: COMPARATOR
Intervention: Sliding screw device alone (Control)
Number of subjects: 112
Study 12860582 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride 1500 mg with chondroitin sulfate 1200 mg
Number of subjects: 0
Study 12860582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10980853 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 0
Study 10980853 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy (antiarrhythmic drug therapy)
Number of subjects: 0
Study 7486901 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (CAM) 100 mg, twice a day for 8 weeks
Number of subjects: 31
Study 7486901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 2344171 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid (one daily intravenous dose)
Number of subjects: 65
Study 2344171 — intervention group
Group type: COMPARATOR
Intervention: Nafcillin (multidose)
Number of subjects: 65
Study 7008650 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical current (varied for each protocol)
Number of subjects: 60
Study 7008650 — intervention group
Group type: COMPARATOR
Intervention: No electrical current (control group)
Number of subjects: 60
Study 29117996 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated ultrafiltration (ultrafiltration rate 13.6 ± 3.9 ml·kg⁻¹·h⁻¹)
Number of subjects: 8
Study 29117996 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolemic dialysis
Number of subjects: 8
Study 27336191 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram treatment
Number of subjects: 300
Study 27336191 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 300
Study 24827902 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon‐lambda‐1a (Lambda)
Number of subjects: 0
Study 24827902 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa‐2a (alfa)
Number of subjects: 0
Study 23010090 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium exposure (5 nights)
Number of subjects: 24
Study 20237174 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and functional task training for 1 hour a day for 10 consecutive working days.
Number of subjects: 11
Study 18092695 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (percutaneous Kirschner-wiring)
Number of subjects: 60
Study 18092695 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (close reduction and immobilisation in plaster splint)
Number of subjects: 60
Study 15946977 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 25 mg/m(2) on days 1 and 8 and epirubicin 60 mg/m(2) on day 1, 3 weekly for six cycles (VE)
Number of subjects: 451
Study 15946977 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m(2) and cyclophosphamide 600 mg/m(2) i.v. on day 1, 3 weekly for six cycles (AC)
Number of subjects: 451
Study 11828245 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g x d(‐1) during 5 d)
Number of subjects: 19
Study 11828245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10452142 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) levels in children with brain injury
Number of subjects: 50
Study 10452142 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy children
Number of subjects: 50
Study 10452142 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin and aldosterone levels in children with brain injury
Number of subjects: 50
Study 10452142 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 50
Study 8733874 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothyroidism induced by half-dose thyroxine replacement therapy (cutting replacement therapy in half)
Number of subjects: 0
Study 8733874 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation (substituting triiodothyronine for thyroxine replacement over a 3-week period, then omitting hormone therapy for 3 weeks)
Number of subjects: 0
Study 1715416 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB, VAB-6, BVP regimen (group A)
Number of subjects: 34
Study 1715416 — intervention group
Group type: COMPARATOR
Intervention: PEB chemotherapy (group B)
Number of subjects: 34
Study 6751239 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 27
Study 6751239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 29989468 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial program (exercise, medication review, and education)
Number of subjects: 13
Study 29989468 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 13
Study 29205150 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidopexy (SH)
Number of subjects: 777
Study 29205150 — intervention group
Group type: COMPARATOR
Intervention: Traditional haemorrhoidectomy (TH)
Number of subjects: 777
Study 26789749 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based treatment (SBT) with praziquantel, coverage 84.2%.
Number of subjects: 75
Study 26789749 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 75
Study 24504198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal linear acceleration at 30 mG
Number of subjects: 16
Study 24504198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal linear acceleration at 1.25 mG
Number of subjects: 16
Study 24504198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal linear acceleration at 10 mG
Number of subjects: 16
Study 24504198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal linear acceleration at 6.5 mG
Number of subjects: 16
Study 22970933 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of the fetal head position
Number of subjects: 450
Study 22970933 — intervention group
Group type: COMPARATOR
Intervention: Standard care (transvaginal digital examination)
Number of subjects: 450
Study 20304540 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 LC-PUFA-enriched dairy products (3g n-3 LC-PUFA/d)
Number of subjects: 51
Study 20304540 — intervention group
Group type: COMPARATOR
Intervention: Control dairy products
Number of subjects: 51
Study 20304540 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 LC-PUFA-enriched dairy products
Number of subjects: 51
Study 17327294 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin 6 mg/kg once daily plus penicillin G 5 million IU x 4
Number of subjects: 174
Study 17327294 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin 6 mg/kg three times daily plus penicillin G 5 million IU x 4
Number of subjects: 174
Study 17327294 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 174
Study 16277774 — intervention group
Group type: EXPERIMENTAL
Intervention: High vitamin C diet
Number of subjects: 32
Study 16277774 — intervention group
Group type: COMPARATOR
Intervention: Low vitamin C diet
Number of subjects: 32
Study 16277774 — intervention group
Group type: EXPERIMENTAL
Intervention: High meat diet
Number of subjects: 32
Study 16277774 — intervention group
Group type: COMPARATOR
Intervention: Low meat diet
Number of subjects: 32
Study 16277774 — intervention group
Group type: EXPERIMENTAL
Intervention: High phytic acid diet
Number of subjects: 32
Study 16277774 — intervention group
Group type: COMPARATOR
Intervention: Low phytic acid diet
Number of subjects: 32
Study 16277774 — intervention group
Group type: COMPARATOR
Intervention: Diet with lowest bioavailability
Number of subjects: 32
Study 16277774 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with highest bioavailability
Number of subjects: 32
Study 12014534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led screening
Number of subjects: 3001
Study 12014534 — intervention group
Group type: COMPARATOR
Intervention: Prompted opportunistic case finding
Number of subjects: 3001
Study 10467991 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk (1.0 g fat/dl, 3.3 g protein/dl)
Number of subjects: 38
Study 10467991 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-fat milk (3.5 g fat/dl, 3.3 g protein/dl)
Number of subjects: 38
Study 10467991 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially vegetable fat and protein-reduced milk (3.5 g fat/dl, 50% vegetable; 2.2 g protein/dl)
Number of subjects: 38
Study 10467991 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-vegetable-fat milk (3.5 g fat/dl, 100% vegetable; 3.0 g protein/dl)
Number of subjects: 38
Study 10467991 — intervention group
Group type: COMPARATOR
Intervention: Low-fat milk
Number of subjects: 38
Study 10467991 — intervention group
Group type: COMPARATOR
Intervention: Milks containing vegetable fat
Number of subjects: 38
Study 10467991 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 38
Study 8316752 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 W/6 min stage
Number of subjects: 11
Study 8316752 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp (15 W per min)
Number of subjects: 11
Study 8316752 — intervention group
Group type: COMPARATOR
Intervention: 50 W/3 min stage
Number of subjects: 11
Study 8316752 — intervention group
Group type: EXPERIMENTAL
Intervention: Various exercise programmes
Number of subjects: 11
Study 8316752 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal and peak oxygen consumption, peak heart rate, rate pressure product, workload and minute ventilation
Number of subjects: 11
Study 2894993 — intervention group
Group type: EXPERIMENTAL
Intervention: WAL801 CL 8 mg b.d. for 15 days
Number of subjects: 10
Study 30287714 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraligamentary injection
Number of subjects: 30
Study 30287714 — intervention group
Group type: COMPARATOR
Intervention: Supraperiosteal injection
Number of subjects: 30
Study 27080209 — intervention group
Group type: EXPERIMENTAL
Intervention: E6005 ointment (0.2%)
Number of subjects: 40
Study 27080209 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 40
Study 25281180 — intervention group
Group type: EXPERIMENTAL
Intervention: Google Glass
Number of subjects: 40
Study 25281180 — intervention group
Group type: COMPARATOR
Intervention: Traditional ultrasound
Number of subjects: 40
Study 23011528 — intervention group
Group type: EXPERIMENTAL
Intervention: Average ICP during the first 48 hours of monitoring
Number of subjects: 499
Study 20175714 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril plus diuretic combination therapy
Number of subjects: 3825
Study 20175714 — intervention group
Group type: COMPARATOR
Intervention: Perindopril monotherapy
Number of subjects: 3825
Study 17910536 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy instruction to individuals
Number of subjects: 38
Study 17910536 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy instruction in small groups in a reciprocal teaching context
Number of subjects: 38
Study 17910536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention programme (15 weekly lessons of 1 hour each for 3 months)
Number of subjects: 38
Study 17910536 — intervention group
Group type: EXPERIMENTAL
Intervention: General reading comprehension ability
Number of subjects: 38
Study 16040444 — intervention group
Group type: EXPERIMENTAL
Intervention: Michigan type splint
Number of subjects: 38
Study 16040444 — intervention group
Group type: EXPERIMENTAL
Intervention: NTI splint
Number of subjects: 38
Study 16040444 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both splint designs
Number of subjects: 38
Study 12160622 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 115
Study 10096374 — intervention group
Group type: EXPERIMENTAL
Intervention: finasteride 5 mg daily
Number of subjects: 41
Study 10096374 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study 9188359 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized discharge teaching plus videotape
Number of subjects: 50
Study 9188359 — intervention group
Group type: COMPARATOR
Intervention: Individualized discharge teaching
Number of subjects: 50
Study 2020339 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-free acetate dialysis
Number of subjects: 0
Study 2020339 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate dialysis
Number of subjects: 0
Study 6282455 — intervention group
Group type: COMPARATOR
Intervention: MACC chemotherapy only (methotrexate, doxorubicin, cyclophosphamide, and lomustine)
Number of subjects: 109
Study 6282455 — intervention group
Group type: EXPERIMENTAL
Intervention: MACC plus levamisole (LMS)
Number of subjects: 109
Study 6282455 — intervention group
Group type: EXPERIMENTAL
Intervention: MACC plus Corynebacterium parvum (CP)
Number of subjects: 109
Study 31836012 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased first trimester leptin
Number of subjects: 140
Study 31836012 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased first trimester resistin
Number of subjects: 140
Study 31836012 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased first trimester visfatin
Number of subjects: 140
Study 31836012 — intervention group
Group type: COMPARATOR
Intervention: Leptin
Number of subjects: 140
Study 31836012 — intervention group
Group type: COMPARATOR
Intervention: Resistin
Number of subjects: 140
Study 31836012 — intervention group
Group type: COMPARATOR
Intervention: Visfatin
Number of subjects: 140
Study 27860068 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 109
Study 27860068 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP (CPAP withdrawal)
Number of subjects: 109
Study 26163437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-chemoradiotherapy (CRT) with weekly cisplatin (30 mg/m(2)/w)
Number of subjects: 44
Study 26163437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab-radiotherapy (ERT) with loading dose of 400 mg/m(2) followed by weekly doses of 250 mg/m(2)
Number of subjects: 44
Study 26163437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab-radiotherapy (ERT)
Number of subjects: 44
Study 26163437 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-chemoradiotherapy (CRT)
Number of subjects: 44
Study 23395639 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0
Study 23395639 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa
Number of subjects: 0
Study 21177284 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided TAP block
Number of subjects: 273
Study 21177284 — intervention group
Group type: COMPARATOR
Intervention: Blind IHN block
Number of subjects: 273
Study 19369376 — intervention group
Group type: EXPERIMENTAL
Intervention: High micronutrient treatment (100% RDA)
Number of subjects: 598
Study 19369376 — intervention group
Group type: COMPARATOR
Intervention: Low micronutrient treatment (15% RDA)
Number of subjects: 598
Study 19369376 — intervention group
Group type: COMPARATOR
Intervention: n-3 treatments (900 mg alpha-linolenic acid + 100 mg docosahexaenoic acid or 140 mg alpha-linolenic acid)
Number of subjects: 598
Study 18200994 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine
Number of subjects: 80
Study 18200994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracuff lidocaine
Number of subjects: 80
Study 18200994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 80
Study 18200994 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 14762227 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg q.d. a.m.
Number of subjects: 697
Study 14762227 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg q.d. p.m.
Number of subjects: 697
Study 14762227 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 100 mg b.i.d.
Number of subjects: 697
Study 11241051 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy (0.074 mg/kg, subcutaneously, 3 times per week)
Number of subjects: 49
Study 11241051 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 49
Study 9510489 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual chamber pacing in VDD mode
Number of subjects: 15
Study 9510489 — intervention group
Group type: COMPARATOR
Intervention: Unpaced controls
Number of subjects: 15
Study 9152782 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (37.5 mg daily)
Number of subjects: 29
Study 9152782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 2376254 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline via Nebuhaler (250 micrograms/puff)
Number of subjects: 30
Study 2376254 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol via Volumatic (100 micrograms/puff)
Number of subjects: 30
Study 675213 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol (1.25 mg)
Number of subjects: 37
Study 675213 — intervention group
Group type: EXPERIMENTAL
Intervention: reproterol (2.5 mg)
Number of subjects: 37
Study 675213 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline (2.5 mg)
Number of subjects: 37
Study 675213 — intervention group
Group type: COMPARATOR
Intervention: salbutamol (1.25 mg)
Number of subjects: 37
Study 30945505 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with medication (Diclofenac Diethylamine Emulgel, 3 times a day for 2 weeks)
Number of subjects: 60
Study 30945505 — intervention group
Group type: COMPARATOR
Intervention: Medication group (Diclofenac Diethylamine Emulgel, 3 times a day for 2 weeks)
Number of subjects: 60
Study 28145128 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Plate (PP) program with small prizes for selection
Number of subjects: 207
Study 25935840 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (2 or 4 mg kg(‐1))
Number of subjects: 154
Study 25935840 — intervention group
Group type: COMPARATOR
Intervention: Usual care (neostigmine/glycopyrrolate)
Number of subjects: 154
Study 25935840 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 154
Study 22890637 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan (intervention from CONSCIOUS‐1 study)
Number of subjects: 97
Study 21546719 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy (vitamin A, vitamin C, vitamin E)
Number of subjects: 39
Study 21546719 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 39
Study 19018239 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct sirolimus-eluting stent (SES) implantation
Number of subjects: 39
Study 19018239 — intervention group
Group type: COMPARATOR
Intervention: Complementary stenting (CS)
Number of subjects: 39
Study 17517850 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine (200 mg loading dose daily for 3 days, followed by 200 mg weekly for 6 months)
Number of subjects: 490
Study 17517850 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Number of subjects: 490
Study 14739872 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (least feedback)
Number of subjects: 35
Study 14739872 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (intermittent feedback)
Number of subjects: 35
Study 14739872 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (more frequent intermittent feedback)
Number of subjects: 35
Study 14739872 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (constant feedback)
Number of subjects: 35
Study 11549646 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 or 120 mg/d)
Number of subjects: 100
Study 9542478 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 24
Study 9542478 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 10 mg
Number of subjects: 24
Study 9542478 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 15 mg
Number of subjects: 24
Study 9542478 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan (all doses)
Number of subjects: 24
Study 9542478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7864934 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 20 mg daily
Number of subjects: 381
Study 7864934 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 381
Study 3212150 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (37.5, 70 mg)
Number of subjects: 90
Study 3212150 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (100, 200 mg)
Number of subjects: 90
Study 3212150 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine (100, 200 mg)
Number of subjects: 90
Study 3212150 — intervention group
Group type: EXPERIMENTAL
Intervention: Protriptyline (10, 20 mg)
Number of subjects: 90
Study 3212150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 29990038 — intervention group
Group type: EXPERIMENTAL
Intervention: CROification algorithm using the CRO feature map with linear SVM
Number of subjects: 0
Study 29990038 — intervention group
Group type: COMPARATOR
Intervention: Gaussian kernel SVM
Number of subjects: 0
Study 27995519 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide 120 mg subcutaneously every 28 days
Number of subjects: 309
Study 27995519 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 309
Study 25591130 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip strengthening exercise program
Number of subjects: 72